Legend Biotech (LEGN) Appoints Ying Huang to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
December 30, 2021 8:30 AM ESTSOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotechs Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotechs Board of Directors. Dr. Huang will serve as a Class I director.
We are delighted to have Dr. Huang join our Board of Directors, said Sally Wang, Chairwoman of Legend Biotech. As Legend Biotechs Chief Executive Officer and Chief Financial Officer, Dr. Huang has been... More
